Health Services Stocks On The Rise With Help From 5 Stocks

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model

All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 79 points (0.5%) at 15,295 as of Wednesday, May 15, 2013, 12:45 PM ET. The NYSE advances/declines ratio sits at 1,703 issues advancing vs. 1,237 declining with 128 unchanged.

The Health Services industry currently sits up 0.1% versus the S&P 500, which is up 0.6%. Top gainers within the industry include Boston Scientific ( BSX), up 3.5%, Abbott Laboratories ( ABT), up 1.6%, Smith & Nephew ( SNN), up 1.4%, Laboratory Corporation of America Holdings ( LH), up 1.4% and Catamaran ( CTRX), up 1.3%. A company within the industry that fell today was Covidien ( COV), up 0.51.

TheStreet Ratings group would like to highlight 5 stocks pushing the industry higher today:

5. Stryker Corporation ( SYK) is one of the companies pushing the Health Services industry higher today. As of noon trading, Stryker Corporation is up $0.49 (0.71) to $69.70 on average volume Thus far, 698,666 shares of Stryker Corporation exchanged hands as compared to its average daily volume of 1.6 million shares. The stock has ranged in price between $69.11-$69.81 after having opened the day at $69.12 as compared to the previous trading day's close of $69.21.

Stryker Corporation, a medical technology company, provides reconstructive, medical and surgical, and neurotechnology and spine products for doctors, hospitals, and other healthcare facilities. Stryker Corporation has a market cap of $25.9 billion and is part of the health care sector. The company has a P/E ratio of 21.0, above the S&P 500 P/E ratio of 17.7. Shares are up 26.2% year to date as of the close of trading on Tuesday. Currently there are 13 analysts that rate Stryker Corporation a buy, no analysts rate it a sell, and 13 rate it a hold.

TheStreet Ratings rates Stryker Corporation as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, good cash flow from operations, largely solid financial position with reasonable debt levels by most measures, solid stock price performance and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Stryker Corporation Ratings Report now.

Exclusive Offer: Jim Cramer's 'go-to' small/mid-cap guru Bryan Ashenberg only buys stocks he thinks could return 50-100%. See his top picks for 14-days FREE.

4. As of noon trading, St Jude Medical ( STJ) is up $0.52 (1.13) to $46.57 on average volume Thus far, 1.1 million shares of St Jude Medical exchanged hands as compared to its average daily volume of 2.4 million shares. The stock has ranged in price between $45.89-$46.58 after having opened the day at $46.13 as compared to the previous trading day's close of $46.05.

St. Jude Medical, Inc. develops, manufactures, and distributes cardiovascular and implantable neurostimulation medical devices worldwide. It operates in two divisions, Cardiovascular and Ablation Technologies, and Implantable Electronic Systems. St Jude Medical has a market cap of $12.8 billion and is part of the health care sector. The company has a P/E ratio of 18.0, above the S&P 500 P/E ratio of 17.7. Shares are up 27.4% year to date as of the close of trading on Tuesday. Currently there are 10 analysts that rate St Jude Medical a buy, 1 analyst rates it a sell, and 12 rate it a hold.

TheStreet Ratings rates St Jude Medical as a buy. The company's strengths can be seen in multiple areas, such as its increase in net income, notable return on equity, attractive valuation levels, increase in stock price during the past year and growth in earnings per share. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full St Jude Medical Ratings Report now.

Exclusive Offer: Jim Cramer's 'go-to' small/mid-cap guru Bryan Ashenberg only buys stocks he thinks could return 50-100%. See his top picks for 14-days FREE.

3. As of noon trading, Agilent Technologies ( A) is up $1.76 (4.00) to $45.73 on heavy volume Thus far, 6.1 million shares of Agilent Technologies exchanged hands as compared to its average daily volume of 3.6 million shares. The stock has ranged in price between $44.89-$46.49 after having opened the day at $44.90 as compared to the previous trading day's close of $43.97.

Agilent Technologies, Inc. provides bio-analytical and electronic measurement solutions and services to the life sciences, chemical analysis, diagnostics and genomics, communications, and electronics industries worldwide. Agilent Technologies has a market cap of $14.9 billion and is part of the health care sector. The company has a P/E ratio of 13.8, below the S&P 500 P/E ratio of 17.7. Shares are up 7.4% year to date as of the close of trading on Tuesday. Currently there are 14 analysts that rate Agilent Technologies a buy, no analysts rate it a sell, and none rate it a hold.

TheStreet Ratings rates Agilent Technologies as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels, expanding profit margins and good cash flow from operations. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Agilent Technologies Ratings Report now.

Exclusive Offer: Jim Cramer's 'go-to' small/mid-cap guru Bryan Ashenberg only buys stocks he thinks could return 50-100%. See his top picks for 14-days FREE.

2. As of noon trading, Aetna ( AET) is up $0.70 (1.18) to $60.09 on average volume Thus far, 1.8 million shares of Aetna exchanged hands as compared to its average daily volume of 3.4 million shares. The stock has ranged in price between $59.11-$60.09 after having opened the day at $59.51 as compared to the previous trading day's close of $59.39.

Aetna Inc. operates as a diversified health care benefits company in the United States. The company operates in three segments: Health Care, Group Insurance, and Large Case Pensions. Aetna has a market cap of $19.3 billion and is part of the health care sector. The company has a P/E ratio of 12.2, below the S&P 500 P/E ratio of 17.7. Shares are up 28.2% year to date as of the close of trading on Tuesday. Currently there are 10 analysts that rate Aetna a buy, no analysts rate it a sell, and 6 rate it a hold.

TheStreet Ratings rates Aetna as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, revenue growth, attractive valuation levels, largely solid financial position with reasonable debt levels by most measures and growth in earnings per share. We feel these strengths outweigh the fact that the company shows low profit margins. Get the full Aetna Ratings Report now.

Exclusive Offer: Jim Cramer's 'go-to' small/mid-cap guru Bryan Ashenberg only buys stocks he thinks could return 50-100%. See his top picks for 14-days FREE.

1. As of noon trading, Thermo Fisher Scientific ( TMO) is up $1.39 (1.64) to $86.10 on average volume Thus far, 1.2 million shares of Thermo Fisher Scientific exchanged hands as compared to its average daily volume of 2.6 million shares. The stock has ranged in price between $84.25-$86.12 after having opened the day at $84.64 as compared to the previous trading day's close of $84.71.

Thermo Fisher Scientific Inc. provides analytical instruments, equipment, reagents and consumables, software, and services for research, manufacture, analysis, discovery, and diagnostics. Thermo Fisher Scientific has a market cap of $30.3 billion and is part of the health care sector. The company has a P/E ratio of 23.4, above the S&P 500 P/E ratio of 17.7. Shares are up 32.8% year to date as of the close of trading on Tuesday. Currently there are 12 analysts that rate Thermo Fisher Scientific a buy, no analysts rate it a sell, and none rate it a hold.

TheStreet Ratings rates Thermo Fisher Scientific as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, impressive record of earnings per share growth, increase in net income, revenue growth and largely solid financial position with reasonable debt levels by most measures. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full Thermo Fisher Scientific Ratings Report now.

Exclusive Offer: Jim Cramer's 'go-to' small/mid-cap guru Bryan Ashenberg only buys stocks he thinks could return 50-100%. See his top picks for 14-days FREE.

If you are interested in one of these 5 stocks, ETFs may be of interest. Investors who are bullish on the health services industry could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health services industry could consider ProShares Ultra Short Health Care ( RXD).

A reminder about TheStreet Ratings group: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.
null

If you liked this article you might like

Stocks Need to Move Lower to Be Able to Move Higher Again: Market Recon

Stocks Need to Move Lower to Be Able to Move Higher Again: Market Recon

11 Stocks Our Experts Love for November

11 Stocks Our Experts Love for November

Remember That Bumps in the Road Are Normal: Market Recon

Remember That Bumps in the Road Are Normal: Market Recon

Smith & Nephew Surges to Record High on Reports of Elliott Stake

Smith & Nephew Surges to Record High on Reports of Elliott Stake

These Stocks Are Ready to Reverse Course

These Stocks Are Ready to Reverse Course